Search for a trial

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to Placebo- Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Primary Objective:To evaluate if treatment with RVX000222 as compared to placebo increases time to thefirst occurrence of narrowly defined MACE. Narrowly defined MACE is defined as a singlecomposite endpoint of CV death or non-fatal MI or stroke.…

NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease a prospective randomized trial

The purpose of this study is to evaluate the effect of high dose RAS-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a…

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus

The overall safety objective of this study is to assess the safety and tolerability of long-term therapy with ticagrelor compared to placebo in patients with T2DM at high risk of CV events, with or without background low-dose ASA therapy. Bleeding…

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes post Worsening Heart Failure

The main objectives of the study are to demonstrate whether sotagliflozin reduces the composite of CV (cardiovascular) death and HHF (hospitalization for heart failure) as compared to placebo in diabetic patients after admission for WHF (worsening…

Patients with Insulin-Treated Diabetes Mellitus and Coronary Artery Disease treated with Drug-Eluting Balloon Post Drug-Eluting Stent Therapy

The aim of this study is to improve clinical outcomes in patients with insulin-treated DM after coronary stent placement in the treatment of coronary artery disease with drug-eluting balloon therapy after stent placement.

A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus

To demonstrate the noninferiority of insulin glargine 300 U/mLin comparison to insulin degludec 100 U/mL on glycemiccontrol and variability in participants with diabetes mellitus

European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently diagnosed type 1 diabetes

Primary objective1. To evaluate efficacy of ILT-101 for the preservation of residual pancreatic β cells function2. To select the optimal regimen of administration of ILT-101.Secondary objectivesTo assess:1. Tregs expansion after an induction period…

A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus (Harmony Outcomes Trial, GLP116174)

Primary: Time to first occurrence of MACE (cardiovascular death, myocardial infarction, or stroke) [Non-inferiority].Secondary: Time to first occurrence of MACE [Superiority], MACE or urgent revascularization for unstable angina, individual…

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the
Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes
Mellitus ('CANVAS-R')

Primary objectiveIn subjects with T2DM receiving standard of care but with inadequate glycemic control and at elevatedrisk of cardiovascular (CV) events to assess the effect of canagliflozin compared to placebo onprogression of albuminuria.Secondary…

DECLARE Dapagliflozin Effect on CardiovascuLAR Events
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

ObjectivesPrimary objectiveThe primary objective is to determine the effect of dapagliflozin relative to placebo oncardiovascular outcomes when added to current background therapy in patients with type 2diabetes mellitus (T2DM) with either…

Diabetes and WELLbeing

Decrease disease-burden in the diabetes type 2 population, by improving quality of life, physical activity levels, physical performance and the overall quality of diabetes care. Thereby empowering the diabetes population to better self-manage their…

A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes

Primary Objective • To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) or weight in patients with T2D following 65 weeks of treatment. The non-inferiority margins…

Optimal blood pressure control through improved adherence to antihypertensive medication after shared decision making in people with type 2 diabetes (T2DM)

To improve BP control and health related quality of life by offering a nurse-led patient-centred supportive intervention to people with T2DM who are objectively non-adherent to their antihypertensive medication and/or life style behaviour…

Use of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes and microalbuminuria

The objective of this study is to determine whether monomeric and oligomeric flavanols have a beneficial effect on renal-endothelial function in the dietary management of T2D, as reflected by improvement of AER and renal-endothelial biomarkers